Could a bone drug help fight ovarian cancer?
NCT ID NCT05053750
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether adding zoledronic acid (a bone-strengthening drug) to standard chemotherapy and a targeted therapy can help women with ovarian cancer that no longer responds to platinum-based treatment. The study involves 14 participants and focuses on measuring immune cells in tumors. It is an early-phase trial, so the main goal is to see how the body responds, not yet to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zoledronic acid (added to paclitaxel and bevacizumab)
What this could lead to
If it works, this could point toward a new combination therapy for hard-to-treat ovarian cancer that has stopped responding to platinum-based chemo.
What could go wrong
This is a very early, small pilot study with only 14 participants. It is designed mainly to measure immune cell counts, not to prove the treatment works. The added drug may cause side effects like bone pain or kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States